Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a report issued on Thursday,Benzinga reports. The firm currently has a $13.00 price target on the stock.

Separately, HC Wainwright raised their price objective on Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, March 24th.

Enlivex Therapeutics Trading Down 6.2 %

Enlivex Therapeutics stock opened at $0.89 on Thursday. The firm has a market capitalization of $19.01 million, a price-to-earnings ratio of -0.91 and a beta of 0.85. The firm has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.22. Enlivex Therapeutics has a 1-year low of $0.81 and a 1-year high of $4.21.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). On average, equities research analysts forecast that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Trading of Enlivex Therapeutics

Large investors have recently bought and sold shares of the company. Two Sigma Securities LLC purchased a new position in shares of Enlivex Therapeutics during the fourth quarter valued at approximately $26,000. Renaissance Technologies LLC increased its position in Enlivex Therapeutics by 112.6% during the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after buying an additional 84,203 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Enlivex Therapeutics during the fourth quarter valued at $742,000. 1.02% of the stock is owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.